Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Net Income towards Common Stockholders: 2020-2023

Historic Net Income towards Common Stockholders for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$54.8 million.

  • Immuneering's Net Income towards Common Stockholders fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
  • According to the latest figures from FY2023, Immuneering's Net Income towards Common Stockholders is -$54.8 million, which was down 8.50% from -$50.5 million recorded in FY2022.
  • In the past 5 years, Immuneering's Net Income towards Common Stockholders ranged from a high of -$17.0 million in FY2020 and a low of -$54.8 million during FY2023.
  • Over the past 3 years, Immuneering's median Net Income towards Common Stockholders value was -$50.5 million (recorded in 2022), while the average stood at -$46.3 million.
  • Data for Immuneering's Net Income towards Common Stockholders shows a maximum YoY slumped of 96.81% (in 2021) over the last 5 years.
  • Yearly analysis of 4 years shows Immuneering's Net Income towards Common Stockholders stood at -$17.0 million in 2020, then tumbled by 96.81% to -$33.5 million in 2021, then plummeted by 50.63% to -$50.5 million in 2022, then fell by 8.50% to -$54.8 million in 2023.